Skip to content
Medical Health Aged Care

Preventing falls and Standing Tall: what we can do to reduce our falls risk – expert available for comment

Neuroscience Research Australia (NeuRA) < 1 mins read

Falls injuries cost our health system $4.7 billion in 2020-21 and are leading cause of injury hospitalisations and death. That’s according to figures just released by the Australian Institute for Health and Welfare. But, what can we do to improve these national figures and reduce our own falls risk? NeuRA’s Professor Kim Delbaere is a Senior Principal Research Scientist and Director of Innovation and Translation at the Falls, Balance and Injury Research Centre is available to answer these questions and talk about the work she and her colleagues are doing in this space.  

Prof Delbaere has qualifications in rehabilitation sciences and physiotherapy and completed her PhD on falls in older people. Her research has contributed to the understanding of physical, psychological and cognitive factors causing falls. Her multidisciplinary approach incorporates elements from physiotherapy, psychology, brain imaging and software engineering towards preventing falls and promoting healthy ageing. Prof Delbaere developed the StandingTall app-based program for fall prevention and this year published research on strategies to prevent falls, including walking backwards.


About us:

About NeuRA

Neuroscience Research Australia (NeuRA) is an independent, not-for-profit research institute based in Sydney aiming to prevent, treat and cure brain and nervous system diseases, disorders and injuries through medical research. To learn more about NeuRA: www.neura.edu.au 


Contact details:

Beatrix Kates
Communications and PR Manager
0421 320 769
b.kates@neura.edu.au

 

Katana Smith
Senior Media and PR Advisor
0452 140 477 
katana.smith@neura.edu.au

Media

More from this category

  • Biotechnology, Medical Health Aged Care
  • 09/12/2024
  • 15:45
Jane Morgan Management

NEXSEN Biotech Announces Pre-IPO Fundraising to Revolutionise Point-of-Care Diagnostics

Sydney, Australia – 9December, 2024 |NEXSEN Biotech Pty Ltd (“NEXSEN”), a pioneering diagnostics company, is excited to announce the launch of its pre-IPO fundraising round, targeting $2 million to $3 million. With a mission to improve global health outcomes, NEXSEN is set to deliver cutting-edge point-of-care diagnostic solutions that address critical unmet medical needs. At the heart of NEXSEN's innovation is StrepSure®, the world's first rapid diagnostic test for Group B Streptococcus (“GBS”). This revolutionary technology leverages advanced nanoparticle engineering and aptamer discovery, ensuring quick, accurate, and cost-effective diagnosis at the point of care. StrepSure® is poised to make life-saving…

  • Government Federal, Medical Health Aged Care
  • 09/12/2024
  • 12:14
Catholic Health Australia

CHA backs AMA push for greater access to out-of-hospital care

Catholic Health Australia supports the Australian Medical Association’s call for greater access to out-of-hospital care for patients, outlined in its position paper released today. “We have been calling for reform to out-of-hospital care for the past year and are pleased to see the sector unite around this issue,” said Catholic Health Australia CEO Jason Kara. “Treatments like chemotherapy, dialysis, wound care, palliative care and post-surgical rehab can be conducted safely at home with better outcomes - but millions of patients are missing out. “We urgently need reforms that allow patients and their doctors to choose where they receive their care,…

  • Medical Health Aged Care
  • 09/12/2024
  • 10:55
Monash University

Monash Expert: Australia’s growing arthritis burden

The number of people living with arthritis in Australia is projected to increase by a third by 2040, suggests a modelling study, published in The Lancet Rheumatology. The model projects about 5.4 million Australians will have arthritis in 2040, 1.3 million (31 per cent) more than the estimated number of cases for 2025. Annual health system spending on osteoarthritis – the most common type of arthritis, and rheumatoid arthritis, the most common type of inflammatory arthritis – is forecast to exceed AUD $11.9 billion by 2040, if current spending levels continue, estimated at AUD $2,100 per person with osteoarthritis and…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.